JP2019505527A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505527A5
JP2019505527A5 JP2018537750A JP2018537750A JP2019505527A5 JP 2019505527 A5 JP2019505527 A5 JP 2019505527A5 JP 2018537750 A JP2018537750 A JP 2018537750A JP 2018537750 A JP2018537750 A JP 2018537750A JP 2019505527 A5 JP2019505527 A5 JP 2019505527A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018537750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505527A (ja
JP7252760B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/014007 external-priority patent/WO2017127468A1/en
Publication of JP2019505527A publication Critical patent/JP2019505527A/ja
Publication of JP2019505527A5 publication Critical patent/JP2019505527A5/ja
Priority to JP2021211379A priority Critical patent/JP7366988B2/ja
Application granted granted Critical
Publication of JP7252760B2 publication Critical patent/JP7252760B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018537750A 2016-01-22 2017-01-19 抗凝固因子xi抗体 Active JP7252760B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021211379A JP7366988B2 (ja) 2016-01-22 2021-12-24 抗凝固因子xi抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281842P 2016-01-22 2016-01-22
US62/281,842 2016-01-22
PCT/US2017/014007 WO2017127468A1 (en) 2016-01-22 2017-01-19 Anti-coagulation factor xi antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021211379A Division JP7366988B2 (ja) 2016-01-22 2021-12-24 抗凝固因子xi抗体

Publications (3)

Publication Number Publication Date
JP2019505527A JP2019505527A (ja) 2019-02-28
JP2019505527A5 true JP2019505527A5 (enExample) 2020-02-27
JP7252760B2 JP7252760B2 (ja) 2023-04-05

Family

ID=57963475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018537750A Active JP7252760B2 (ja) 2016-01-22 2017-01-19 抗凝固因子xi抗体
JP2021211379A Active JP7366988B2 (ja) 2016-01-22 2021-12-24 抗凝固因子xi抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021211379A Active JP7366988B2 (ja) 2016-01-22 2021-12-24 抗凝固因子xi抗体

Country Status (15)

Country Link
US (2) US10053515B2 (enExample)
EP (1) EP3405498A1 (enExample)
JP (2) JP7252760B2 (enExample)
KR (1) KR20180104036A (enExample)
CN (2) CN108884169B (enExample)
AR (1) AR107505A1 (enExample)
AU (1) AU2017209083A1 (enExample)
BR (1) BR112018014810A2 (enExample)
CA (1) CA3010224A1 (enExample)
JO (1) JOP20170013B1 (enExample)
MA (1) MA43660A (enExample)
MX (2) MX378572B (enExample)
RU (2) RU2757314C2 (enExample)
TW (1) TWI736575B (enExample)
WO (1) WO2017127468A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160131B1 (ar) 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
US11786551B2 (en) 2017-09-26 2023-10-17 The Trustees Of The University Of Pennsylvania Methods for treating heart disease via redirected T cell immunotherapies
CN113227150B (zh) * 2018-08-09 2023-07-28 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
JP7440509B2 (ja) 2018-11-09 2024-02-28 ベス イスラエル デアコネス メディカル センター Cdcp1-標的化療法
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
AU2020211905A1 (en) * 2019-01-21 2021-08-05 Aronora Inc. Novel humanized antibodies against factor XI having anti-thrombotic and anti-inflammatory effects and uses thereof
US20220106398A1 (en) * 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
EP3957652A4 (en) 2019-04-16 2023-06-21 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN114761036B (zh) 2019-09-23 2025-09-30 宾夕法尼亚大学董事会 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
BR112022005423A2 (pt) 2019-09-23 2022-06-21 Univ Pennsylvania Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
CN122124233A (zh) * 2020-07-03 2026-06-02 苏州康宁杰瑞生物科技有限公司 凝血因子xi (fxi)结合蛋白
CN118414168A (zh) * 2021-10-22 2024-07-30 里珍纳龙药品有限公司 因子xi a2结构域结合抗体和其使用方法
US20250034277A1 (en) * 2021-11-30 2025-01-30 Suzhou Alphamab Co., Ltd. Method for preventing and/or treating thromboembolic diseases

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク,インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
CA2591813A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR101652125B1 (ko) 2007-09-26 2016-08-29 우드라이 파마 게엠베하 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
CA2705851C (en) 2007-11-21 2016-11-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
AU2009335643B2 (en) 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
CN102559720B (zh) * 2010-12-16 2015-05-13 中国科学院福建物质结构研究所 人源凝血因子xi催化结构域的表达、纯化及结晶
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
ES2929575T3 (es) 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
HRP20250164T1 (hr) * 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
ES2588484T3 (es) 2012-04-13 2016-11-03 Rottapharm Biotech S.R.L. Anticuerpo anti-ADAMTS-5, derivados y usos del mismo
US9783614B2 (en) * 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. Egfrに結合する抗原結合蛋白質
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
BR112016021576A2 (pt) 2014-03-20 2017-10-10 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento?
MX394895B (es) 2014-06-03 2025-03-24 Xbiotech Inc Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
JOP20160131B1 (ar) 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors

Similar Documents

Publication Publication Date Title
RU2018129874A (ru) Антитела против фактора свертывания xi
JP7293122B2 (ja) 補体が媒介する疾患および障害を処置するための方法
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
HRP20200241T1 (hr) Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti
JP2020062036A5 (enExample)
JP2019527194A5 (enExample)
JP2019513726A5 (enExample)
JP2011207882A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2014511179A5 (enExample)
KR102296017B1 (ko) 혈관 질환 및 이에 따른 합병증 치료
JP2018508188A5 (enExample)
JP2018529661A5 (enExample)
JP2015503909A5 (enExample)
JP2021527640A5 (enExample)
JP2017507131A5 (enExample)
JP2017113019A5 (enExample)
JP2021510736A5 (enExample)
JP2013519367A5 (enExample)
JP2010501164A5 (enExample)
JP2022512647A5 (enExample)
JP2016094424A5 (enExample)
JP2015509960A5 (enExample)
JPWO2020059847A5 (enExample)
JP2024016024A5 (enExample)